Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
NCT06412198Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2024
- Primary completion
- Mar 2029
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of adagrasib, KL-140 and cemiplimab in colorectal cancer (CRC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Safety and adverse events and Objective Response Rate. Started Aug 2024; status: recruiting.
02
Drugs
adagrasibKL-140cemiplimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06412198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06412198.